NASDAQ
27.79USD
-0.29 (-1.03%)
We have scored 16 news catalysts on Amylyx Pharmaceuticals, Inc. (AMLX) over the past 12 months. The biggest single-day move next to one of them came Mar 4, 2026, when AMLX closed +6.7%: “Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point”. Coverage across the window leans mixed (average ticker sentiment −0.06). Most of the impact sits in sector healthcare and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.1B
P/E
—
EPS
—
Beta
-0.20
52W range
10.83-41.14
Day range
27.64–28.81
Open
28.50
Prev close
28.08
Volume
912.4K
Avg volume
2.1M
Dividend
0.00
IPO
2022-01-07
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Amylyx Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for AMLX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
